Disease Burden in Patients with von Willebrand Disease Potentially Eligible for Prophylaxis: Post Hoc Analysis of a European Cross-Sectional Study

Abstract

Recent international guidelines conditionally recommend von Willebrand factor (VWF) prophylaxis for von Willebrand disease (VWD) patients with a history of severe/frequent bleeds. This post hoc analysis of the Cost of VWD Across Europe, a Socioeconomic Study (CVESS; conducted in 2018), assessed patient characteristics and disease burden in patients aged >1 year with congenital VWD not receiving but potentially eligible for prophylaxis based on severe/frequent bleeds, and those receiving prophylaxis in the previous 12 months. Data were collected using medical records and a patient questionnaire. Patients considered potentially prophylaxis-eligible (n = 102) experienced more bleeds than patients receiving prophylaxis (n = 229) and were more likely to be admitted to the hospital due to bleeding events in the prior 12 months. Quality of life and work productivity were similar between the two groups. Logistic regression analysis showed that the prophylaxis-eligible group was more likely to have poor joint function and moderate chronic pain than the prophylaxis group. This retrospective study suggests that 1/7 patients not receiving VWF prophylaxis had a higher disease burden than patients receiving prophylaxis and would potentially benefit from prophylaxis.

Keywords

von Willebrand disease von Willebrand factor prophylaxis disease burden quality of life healthcare resource utilization

Introduction

von Willebrand disease (VWD) is a hereditary bleeding disorder caused by deficiency or dysfunction of von Willebrand factor (VWF),¹ impairing both primary and secondary hemostasis (platelet adhesion and stabilization of factor VIII, respectively).² The global prevalence of VWD is estimated to be 600-1300 per 100,000 individuals, with 10 per 100,000 individuals who have symptomatic VWD requiring treatment.³ There are three main types of VWD classified according to quantitative or qualitative defects in VWF activity.⁴ The most common bleeding phenotypes in patients with VWD are mucocutaneous bleeding—including epistaxis, easy bruising, and heavy menstrual bleeding—and bleeding after surgery or trauma.⁵ Bleeding phenotypes in VWD vary, however, depending on disease type, age, and sex.⁶ Patients with a severe bleeding phenotype (mostly those with VWD type 2 and type 3) have poorer health-related quality of life than the general population and are at increased risk of bleeds that are life-threatening or can lead to long-term complications.^7–10 In the 2021 international guidelines on the management of VWD, long-term prophylactic VWF replacement was recommended in patients with a history of severe and frequent bleeds.^5,11–13 However, this recommendation was conditional based on the low certainty in evidence of effects.⁵ In particular, there is limited real-world evidence demonstrating the health benefits of long-term prophylaxis in patients with VWD.

The Cost of von Willebrand Disease Across Europe, a Socioeconomic Study (CVESS) was initially established to describe the socioeconomic impact of VWD in five European countries.¹⁴ The objectives of this post hoc analysis of data from CVESS were to describe patient characteristics and disease burden in patients with VWD identified as potentially eligible for prophylaxis according to current VWD management guidelines⁵ but not receiving it compared with those patients receiving prophylaxis; and to assess whether the burden of disease differed significantly between these two identified patient groups.

Methods

Study Design

CVESS was a cross-sectional study conducted in 2018 in France, Germany, Italy, Spain, and the United Kingdom. The study was carried out by the University of Chester (Chester, UK) and overseen by an expert reference group that included medical experts and patient representatives.^14,15 It was endorsed by The Haemophilia Society (London, UK) and the European Haemophilia Consortium (Brussels, Belgium), with ethical oversight from the University of Chester. This manuscript reports findings from a post hoc analysis focusing on a specific subset of CVESS patients with VWD and severe/frequent bleeds who were potentially eligible for VWF prophylaxis, as well as those who had received intermittent or continuous prophylaxis.

Hematologists who were directly responsible for the care of patients with VWD collected medical chart data from the 12 months before the index date (ie the date of consultation), including demographics, clinical information, and direct healthcare resource utilization. Patients (in conjunction with their parents or guardian for children aged <18 years) were invited to complete a paper-based questionnaire designed to capture the impact of VWD on their lives, such as direct and indirect non-medical costs, quality of life, and work impairment. Patients completed the questionnaire in the clinic or at a location of their choice around the time of the index date. The questionnaires were then returned to the investigators and passed on to the University of Chester for analysis.

Patient Population

The inclusion and exclusion criteria were approved by the expert review group and the University of Chester research ethical committee. Patients aged >1 year with a laboratory diagnosis of congenital VWD and known VWD classification were eligible, even if they were participating in a clinical trial at the time of the study. Patients were excluded for reasons such as language barriers, diagnosis of acquired von Willebrand syndrome, or, where applicable, the presence of a physical or mental condition resulting in diminished decision making.¹⁶ All patients (or their parent/guardian if aged <18 years) provided written informed consent.

Two patient subgroups were identified from the overall CVESS population based on prior prophylactic therapy with any product containing VWF. The group considered potentially eligible for prophylaxis (ie the prophylaxis-eligible group) comprised patients with severe and/or frequent bleeds in the 12 months before the index date who were not prescribed prophylaxis. This definition of prophylaxis eligibility was based on that used in the 2021 international guidelines on the management of VWD,⁵ in which frequent bleeding was categorized as at least three joint bleeds, at least two gastrointestinal bleeds, or at least five bleeds in total across a 12 month period.¹⁷ The definition of severe bleeding (hospitalization as the result of a bleed, or any bleed involving critical organs) was adapted to fit the data collected in CVESS from the major bleeding definition used in the 2021 VWD management guidelines: “bleeding requiring hospital admission, requiring surgical intervention, requiring blood transfusion (of at least 2 units), resulting in a drop of ≥2 g/dL in hemoglobin, or resulting in symptoms involving critical areas (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome).”⁵ The prophylaxis group included patients who had received intermittent or continuous prophylaxis to prevent bleeding in the previous 12 months. Intermittent prophylaxis was defined as treatment given to prevent bleeding for periods not exceeding 45 weeks in a year, and continuous prophylaxis was defined as the intention of treating for 52 weeks/year and receiving 85% of the prior defined frequency of infusions for at least 45 weeks/year.¹⁸

Outcome Measures and Statistical Analyses

The sample size for CVESS was based on the maximum feasible number of patients available for recruitment in each country, given that VWD is a rare disease. Missing data were excluded from the analysis and the numbers of patients with observations were reported.

VWD-related clinical outcomes (bleeding events, pain, and joint damage) and patient-reported outcomes (EuroQoL 5-dimension, five-level [EQ-5D-5L] score, using a published value set derived from the general population in England,¹⁹ and the Work Productivity and Activity Impairment questionnaire [WPAI]) were assessed in the two patient groups. Healthcare resource utilization, including the number of treated bleeds, was assessed during the 12 months before the index date.

Descriptive statistics were used to compare demographic and clinical characteristics between the prophylaxis-eligible and prophylaxis groups. Categorical variables were described as frequencies and percentages, and continuous variables were presented as mean (standard deviation [SD]). T-tests for continuous variables and chi² tests for categorical variables with two-sided p-values < 0.05 were used to assess statistical significance, with no correction for multiple comparisons.

Multivariable logistic regression models were performed to determine whether patient outcomes differed significantly between the prophylaxis-eligible and prophylaxis groups, controlling for demographic, clinical, and center-related factors. Stepwise selection was used to eliminate variables using the Wald test with a p-value threshold for inclusion set at 0.1. Following this, model goodness of fit statistics and variance inflation factor were assessed for the variables included in the model (Supplementary Table 4b and 4c).

Results

Patient Demographics and Clinical Characteristics

In total, 974 patients were enrolled in CVESS, of whom 229 were receiving intermittent or continuous VWF prophylaxis (Figure 1). Of the remaining 745 patients, 102 were considered potentially eligible for prophylaxis based on the predefined criteria in this analysis for severity and/or frequency of bleeding.

Figure 1.

Patient flow chart. Of the total 974 patients with VWD enrolled in CVESS, 229 received prophylaxis and 102 patients were considered potentially eligible for prophylaxis based on the severity or frequency of bleeding reported in the 12 months before the index date. More than one category of severe and/or frequent bleed could be reported for each patient. CNS, central nervous system; CVESS, Cost of von Willebrand Disease Across Europe, a Socioeconomic Study; GI, gastrointestinal.

Demographic and clinical characteristics of the prophylaxis-eligible and prophylaxis groups are presented in Table 1 and Supplementary Table 1. Mean age in the prophylaxis-eligible group was higher than in the prophylaxis group, with a higher percentage of patients aged ≥65 years. In the UK, there was a higher proportion of patients in the prophylaxis-eligible group; in Germany, more patients were in the prophylaxis group than in the prophylaxis-eligible group.

Table 1.

Baseline Demographics and Disease Characteristics in Patients Considered Potentially Eligible for Prophylaxis but not Receiving it, Compared with Patients who Received Prophylaxis in the Previous 12 Months.

	Patients Eligible for Prophylaxis(n = 102)	Patients who Received Prophylaxis(n = 229)	p-Value^a
Age, years
Mean (SD)	38.0 (20.2)	32.0 (15.5)	0.004
Median (range)	36 (5–85)	31 (2–68)
Age group, n (%), years
<18	22 (21.6)	52 (22.7)	0.818
18–44	39 (38.2)	123 (53.7)	0.009
45–64	27 (26.5)	48 (21.0)	0.269
≥65	14 (13.7)	6 (2.6)	<0.001
Sex, n (%)
Male	57 (55.9)	122 (53.5)	0.660
Female	45 (44.1)	107 (46.7)	0.660
Height, mean (SD), m	1.7 (0.2)	1.7 (0.2)	0.226
Ethnicity
White/Caucasian	87 (85.3)	189 (82.5)	0.533
Black/Afro-Caribbean	7 (6.9)	13 (5.7)	0.676
Middle Eastern	4 (3.9)	11 (4.8)	0.722
Asian
Indian subcontinent	1 (1.0)	6 (2.6)	0.338
Other	1 (1.0)	3 (1.3)	0.800
Mixed	1 (1.0)	5 (2.2)	0.449
Prefer not to answer	1 (1.0)	2 (0.9)	0.924
Country, n (%)
Germany	4 (3.9)	33 (14.4)	0.005
Spain	15 (14.7)	29 (12.7)	0.613
France	13 (12.7)	34 (14.8)	0.613
UK	35 (34.3)	33 (14.4)	<0.001
Italy	35 (34.3)	100 (43.7)	0.110
VWD type, n (%) Type 1 Type 2A Type 2B Type 2M Type 2N Type 2 unconfirmed subtype Type 3	33 (32.4) 19 (18.6) 18 (17.6) 14 (13.7) 5 (4.9) 3 (2.9) 10 (9.8)	63 (27.5) 47 (20.5) 29 (12.7) 27 (11.8) 15 (6.6) 1 (0.4) 47 (20.5)	0.370 0.690 0.230 0.622 0.561 0.054 0.017
Physician-assessed disease severity, n (%)
Mild (does not interfere with most activities)	28 (27.5)	102 (44.5)	0.003
Moderate (interferes with many activities)	64 (62.7)	99 (43.2)	0.001
Severe (unable to engage in normal activities)	10 (9.8)	28 (12.2)	0.523
Chronic pain level, n (%)
None	19 (18.6)	71 (31.0)	0.019
Mild	44 (43.1)	108 (47.2)	0.498
Moderate	36 (35.3)	46 (20.1)	0.003
Severe	3 (2.9)	4 (1.7)	0.486
Joints with limited range of motion
≥1 reported, n (%)	38 (37.3)	38 (16.6)	<0.001
Number of joints if ≥1 reported, mean (SD)	2.3 (2.3)	1.9 (1.2)	0.347
Target joints
≥1 reported, n (%)	24 (23.5)	24 (10.5)	0.002
Number of joints if ≥1 reported, mean (SD)	2.3 (2.6)	1.6 (0.9)	0.232
Chronically damaged joints
≥1 reported, n (%)	36 (35.3)	44 (19.2)	0.002
Number of joints if ≥1 reported, mean (SD)	1.9 (2.2)	1.6 (0.8)	0.378

p-value threshold for statistical significance set at <0.05. SD, standard deviation; VWD, von Willebrand disease.

With respect to VWD type distributions, there was a lower percentage of patients with type 3 VWD in the prophylaxis-eligible group than in the prophylaxis group. However, prophylaxis-eligible patients were more likely to have moderate disease as assessed by the treating physician (rather than mild disease, which was more frequently reported in the prophylaxis group), in addition to higher levels of chronic pain and/or joint damage than patients receiving prophylaxis. Overall, mental and behavioral disorders (including anxiety and depression) were the most reported concomitant conditions in both groups. In general, patients in the prophylaxis-eligible group were more likely to have comorbidities such as mental and behavioral disorders and diseases of circulatory system than those receiving prophylaxis (Supplementary Table 2).

Treated Bleeds and Healthcare Resource Utilization

Frequency of bleeding and bleed severity (defined on the basis of bleed-related hospitalization) were inclusion criteria for the prophylaxis-eligible group. As expected, therefore, the mean (SD) number of treated bleeds in the 12 months before the index date was significantly higher in prophylaxis-eligible patients (5.5 [4.3]) than in patients receiving prophylaxis (1.5 [2.2]); p < 0.001). Similarly, patients in the prophylaxis-eligible group were more likely to be admitted to hospital due to bleeding in the 12 months before the index date than patients receiving prophylaxis (p < 0.001), with correspondingly more days in hospital and intensive care units due to bleeding (p < 0.001; Table 2).

Table 2.

Hospitalizations and Consultations in Patients Considered Potentially Eligible for Prophylaxis but not Receiving it, Compared with Patients who Received Prophylaxis in the Previous 12 Months.

	Patients Eligible for Prophylaxis (n = 102)	Patients who Received Prophylaxis (n = 229)	p-Value^a
Hospitalizations
Hospitalized due to bleeding, n (%)	78 (76.5)	64 (27.9)	<0.001
Days in hospital due to bleeding, mean (SD)	7.1 (12.9)	1.3 (3.9)	<0.001
Days in ICU due to bleeding, mean (SD)	4.4 (12.0)	0.3 (1.8)	<0.001
Consultation history, mean (SD)
Planned/routine visits
Treating physician	4.3 (2.3)	4.1 (3.0)	0.409
Nurse specialist	2.5 (1.8)	1.5 (1.9)	<0.001
Unplanned/emergency visits
Treating physician	3.3 (3.1)	3.2 (4.2)	0.960
Nurse specialist	2.1 (2.2)	1.6 (2.5)	0.053

p-value threshold for statistical significance set at <0.05. ICU, intensive care unit; SD, standard deviation.

In the 12 months before the index date, the numbers of unplanned/emergency visits with treating physicians and nurse specialists, and planned visits with physicians were similar for the prophylaxis-eligible and prophylaxis groups (Table 2). Planned nurse specialist visits, however, were more common in patients eligible for prophylaxis but not receiving it (p < 0.001) (Table 2). Outpatient consultations in the 12 months before the index date for dentistry, emergency medicine and acute surgery, general practice, general surgery, immunology, otolaryngology, pain management, and physiotherapy were more common in prophylaxis-eligible patients than in patients receiving prophylaxis (p < 0.05; Supplementary Table 3).

Health-Related Quality of Life and Productivity

Around the time of the index date, mean (SD) EQ-5D-5L score was similar in the prophylaxis-eligible group (0.7 [0.3]; n = 33) and prophylaxis group (0.7 [0.3]; n = 59; p = 0.345). WPAI scores were also similar in both groups (Figure 2).

Figure 2.

Productivity at the index date in patients considered potentially eligible for prophylaxis but not receiving it, compared with patients who received prophylaxis in the previous 12 months. SD, standard deviation; WPAI, Work Productivity and Activity Impairment questionnaire.

Multivariable Regression Analysis

Logistic regressions were performed for outcomes of interest, controlling for factors identified in the stepwise model (Supplementary Table 4a). The results showed that patients eligible for prophylaxis but not receiving it were more likely to have poor joint function and moderate chronic pain than those receiving prophylaxis (Table 3). In addition, patients in the prophylaxis-eligible group were more likely to have planned/routine nurse specialist consultations, pain management, and/or physiotherapy than patients receiving prophylaxis (Table 3).

Table 3.

Summary of the Logistic Regression Analysis Results.

Patient Outcome	Odds Ratio (95% CI)	p-Value
Chronically damaged joints^a	0.757 (0.556–1.031)	0.077
Target joints^a	0.694 (0.467–1.033)	0.072
Joints with limited range of motion^a	0.740 (0.566–0.966)	0.027
Chronic pain^b
Mild pain	0.555 (0.263–1.175)	0.124
Moderate pain	0.299 (0.127–0.703)	0.006
Severe pain	0.200 (0.024–1.634)	0.133
Planned/routine consultations: physician^a	0.991 (0.885–1.110)	0.874
Planned/routine consultations: nurse specialist^a	0.767 (0.650–0.906)	0.002
Unplanned/emergency consultations: physician^a	1.008 (0.926–1.097)	0.854
Unplanned/emergency consultations: nurse specialist^a	0.904 (0.793–1.031)	0.132
Outpatient consultations: emergency medicine^a	0.950 (0.859–1.050)	0.314
Outpatient consultations: general practice^a	0.934 (0.840–1.039)	0.211
Outpatient consultations: pain management^a	0.706 (0.520–0.958)	0.026
Outpatient consultations: physiotherapy^a	0.794 (0.624–1.010)	0.060

One additional unit (ie increase in odds of being in prophylaxis group given one additional joint/consultation). ^bVersus no pain.

Discussion

This post hoc analysis shows that one in seven patients with VWD could be eligible for long-term VWF prophylaxis according to the current VWD management guidelines.⁵ The study results suggest that long-term VWF prophylaxis could potentially reduce the burden of severe and frequent bleeds for those patients. This highlights that the common perception of VWD as a ‘mild’ bleeding disorder compared with hemophilia is misleading.²⁰

Patients identified as potentially eligible for prophylaxis in the present study mostly had moderate disease severity and type 1 or 2 VWD, and only a small number of these patients had type 3 VWD. Patients considered potentially eligible for but not receiving prophylaxis also tended to be older than those receiving prophylaxis and were found to have worse health outcomes and a higher disease burden than those receiving prophylaxis in the 12 months before the index date, including greater levels of pain, poorer joint function, more treated bleeds, and more medical consultations. The differences between groups with respect to joint function, chronic pain, and medical consultations remained in the regression analysis when controlling for key demographic and clinical parameters, and center-related factors (country and number of patients seen by physician per month).

The rate of hospitalization for bleeding events in the present analysis was similar to that seen in the randomized PRO.WILL study of VWF prophylaxis, in which 22% of patients receiving on-demand therapy and 20% of patients receiving prophylaxis were hospitalized in the 12 months before baseline.¹⁷ The finding in the present analysis of a greater rate of hospitalizations for bleeding events in patients potentially eligible for prophylaxis but not receiving it compared with those receiving prophylaxis is also consistent with previous data, including a national registry study from Sweden, in which initiation of prophylaxis was associated with a significant reduction in hospitalizations.²¹

Prophylactic VWF replacement was initially recommended in the UK treatment guidelines in 2014 for specific patients, including those with type 3 disease plus hemarthroses, severe epistaxis, women with heavy menstrual bleeding, and those with an ongoing risk factor for bleeding (eg angiodysplasia).²² More recently, the 2021 international guidelines on the management of VWD recommended the use of prophylactic VWF replacement in patients with a history of severe and frequent bleeds.^5,23 The recommendation was conditional, however, due to the low certainty of evidence for a net benefit of long-term prophylaxis in this patient population; most of the studies reviewed were observational, with only one randomized trial (the PRO.WILL study).^17,24 Some researchers have noted that the recommendation is particularly valuable for countries such as the United States, where VWF prophylaxis is not part of routine practice.²⁵ In addition, although VWF prophylaxis has been routinely used for many years in Europe,²⁵ there is still evidence to suggest that in contrast to hemophilia, prophylaxis is under-utilized in patients with VWD and severe disease burden.²⁴ Conversely, the applicability of the recommendation to low- or middle-income countries has been questioned, with authors noting that it will be challenging to implement the recommendation where resources are limited,²⁵ even though the data from the present study indicate a high unmet need for patients with severe and/or frequent bleeds.

When interpreting the data from the present study, it should be borne in mind that it was a post hoc analysis for which data collection (medical chart review and patient questionnaire) was not specifically designed. As such, the definition for severe bleeding was not as broad as the major bleeding definition in the 2021 international guidelines on the management of VWD.⁵ In addition, relatively few patients, particularly from the prophylaxis group, completed the quality of life and productivity questionnaires. It should also be noted that the exact date when prophylaxis was started was not captured during the study, so patients in the prophylaxis group may not have received prophylaxis for the full 12 months before the index date. This is especially the case for patients who had received intermittent prophylaxis rather than continuous treatment. However, patients in the prophylaxis group must have received prophylaxis for sufficient time to satisfy the prophylaxis definitions used in the study. Also, the frequencies of bleeding and bleeding-related hospitalizations were used as criteria for prophylaxis-eligible patients and therefore results concerning the frequencies of treated bleeds and hospitalizations due to bleeds may be biased. Finally, it is also possible that treatment patterns may have changed since the study was conducted in 2018, and that the results of this European study may not be applicable to countries where VWF prophylaxis is not available or in routine clinical use.

Conclusions

This post hoc analysis of CVESS, which was conducted in five European countries, shows that a considerable number of patients with VWD and severe or frequent bleeding were not receiving VWF prophylaxis at the time of data collection, despite its availability in Europe. It should be noted that while this cross-sectional study found differences in the outcomes of patient receiving and not receiving but potentially eligible for prophylaxis, it cannot confirm a causal link between prophylaxis use and better health outcomes. The observed higher disease burden in patients considered potentially eligible but not receiving it than in those receiving prophylaxis, however, does suggest that long-term VWF prophylaxis may improve outcomes in patients with VWD and severe/frequent bleeds.⁵

Supplemental Material

sj-docx-1-cat-10.1177_10760296221130334 - Supplemental material for Disease Burden in Patients with von Willebrand Disease Potentially Eligible for Prophylaxis: Post Hoc Analysis of a European Cross-Sectional Study

Supplemental material, sj-docx-1-cat-10.1177_10760296221130334 for Disease Burden in Patients with von Willebrand Disease Potentially Eligible for Prophylaxis: Post Hoc Analysis of a European Cross-Sectional Study by Ping Du, George Morgan, Sarah Brighton and Shawn X. Sun in Clinical and Applied Thrombosis/Hemostasis

Footnotes

Acknowledgments

The authors would like to thank Françoise Truong Berthoz and Nataliya Kemenyash from Takeda Pharmaceuticals International AG, Zurich, Switzerland, and Spiros Tzivelekis from Takeda Development Center Americas, Inc., Cambridge, MA, USA for their contributions to the interpretation of this post hoc analysis. The authors would also like to thank Emily Back from HCD Economics, Daresbury, UK for providing data analysis support and Sohaib Asghar from HCD Economics, Daresbury, UK for contributing to the data analysis and interpretation. Under the direction of the authors, medical writing support was provided by Joanne Vaughan, BSc, employee of Excel Medical Affairs (Fairfield, CT, USA), and was funded by Takeda Development Center Americas, Inc., Lexington, MA, USA.

Author Contributions

GM and SB contributed to the development of the statistical plan for post hoc analysis, analysis, and development of the report and the manuscript. PD and SXS contributed to conceptualization of the study, study design, critical reviews of the results, and development of the report and the manuscript. All authors approved the final version of the manuscript.

Data Availability

Due to the nature of this retrospective study, data are not available for sharing due to ethical/legal restrictions.

Declaration of Conflicting Interests

PD and SXS are employees of Takeda Development Center Americas, Inc., Cambridge, MA, USA, and hold stock in Takeda. GM and SB are employees of HCD Economics, Daresbury, UK, and received research support from Shire Human Genetic Therapies, Inc., a Takeda company, to perform this analysis.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA (grant number NA).

Ethics Approval

Ethical oversight for CVESS was provided by the University of Chester, Chester, United Kingdom.

Informed Consent

All patients (or their parent/guardian if aged <18 years) provided written informed consent.

Previous Presentation

These data were previously presented in part at the International Society on Thrombosis and Haemostasis (ISTH) Congress; July 9–13, 22; London, UK (PB0825).

ORCID iDs

Sarah Brighton

Shawn X. Sun

Supplemental Material

Supplemental material for this article is available online.

References

James

Goodeve

. von Willebrand disease. Genet Med. 2011;13(5):365-376. doi:10.1097/GIM.0b013e3182035931.

Stockschlaeder

Schneppenheim

Budde

. Update on von Willebrand factor multimers: Focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014;25(3):206-216. doi:10.1097/MBC.0000000000000065.

Orphanet. Von Willebrand disease. Accessed March 31, 2022. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng = EN&Expert = 903.

Sadler

Budde

Eikenboom

, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114. doi:10.1111/j.1538-7836.2006.02146.x.

Connell

Flood

Brignardello-Petersen

, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325. doi:10.1182/bloodadvances.2020003264.

de Wee

Sanders

Mauser-Bunschoten

, et al. WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012;108(4):683-692. doi:10.1160/TH12-04-0244.

de Wee

Mauser-Bunschoten

Van Der Bom

, et al. WiN Study Group. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost. 2010;8(7):1492-1499. doi:10.1111/j.1538-7836.2010.03864.x.

Deforest

Grabell

, et al. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: A cross-sectional study. Haemophilia. 2017;23(1):115-121. doi:10.1111/hae.13062.

van Galen

KPM

de Kleijn

Foppen

, et al. WiN study group. Long-term impact of joint bleeds in von Willebrand disease: A nested case-control study. Haematologica. 2017;102(9):1486-1493. doi:10.3324/haematol.2017.168617.

10.

Leebeek

FWG

Eikenboom

JCJ

. Von Willebrand's disease. N Engl J Med. 2016;375(21):2067-2080. doi:10.1056/NEJMra1601561.

11.

Weyand

Flood

. Von Willebrand disease: Current status of diagnosis and management. Hematol Oncol Clin North Am. 2021;35(6):1085-1101. doi:10.1016/j.hoc.2021.07.004.

12.

Franchini

Seidizadeh

Mannucci

. Prophylactic management of patients with von Willebrand disease. Ther Adv Hematol. 2021;12:20406207211064064. doi:10.1177/20406207211064064.

13.

El Alayli A Brignardello Petersen R Husainat

, et al. Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. Haemophilia. 2022;28(3):373-387. doi:10.1111/hae.14550.

14.

Morgan

Brighton

Laffan

, et al. The Cost of Von Willebrand Disease in Europe: The CVESS Study. Clin Appl Thromb Hemost. 2022;28:10760296221120583. doi:10.1177/10760296221120583.

15.

Willock

Laffan

Goudemand

, et al. An introduction to CVESS: The cost of von Willebrand disease in Europe-a socioeconomic study. Haemophilia. 2019;25(1):163.

16.

Oyebode

. The Mental Capacity Act 2005. Clin Med (Lond). 2006;6(2):130-131. doi:10.7861/clinmedicine.6-2-130.

17.

Peyvandi

Castaman

Gresele

, et al. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019;17(5):391-398. doi:10.2450/2019.0183-18.

18.

Federici

. Prophylaxis in patients with von Willebrand disease: Who, when, how? J Thromb Haemost. 2015;13(9):1581-1584. doi:10.1111/jth.13036.

19.

Devlin

Shah

Feng

, et al. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018;27(1):7-22. doi:10.1002/hec.3564.

20.

Denis

Susen

Lenting

. von Willebrand disease: What does the future hold? Blood. 2021;137(17):2299-2306. doi:10.1182/blood.2020008501.

21.

Holm

Carlsson

Lövdahl

, et al. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network. Haemophilia. 2018;24(4):628-633. doi:10.1111/hae.13473.

22.

Laffan

Lester

O'Donnell

, et al. The diagnosis and management of von Willebrand disease: A United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167(4):453-465. doi:10.1111/bjh.13064.

23.

The Lancet Haematology. Giving von Willebrand disease the attention it deserves. Lancet Haematol. 2021;8(3):e161. doi:10.1016/S2352-3026(21)00031-4.

24.

James

Connell

Flood

, et al. Response to “The 2021 von Willebrand disease guidelines: Clarity and controversy”. Haemophilia. 2022;28(3):371-372. doi:10.1111/hae.14528.

25.

Makris

Hermans

. The 2021 von Willebrand disease guidelines: Clarity and controversy. Haemophilia. 2022;28(1):1-3. doi:10.1111/hae.14465.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB